Relmada Therapeutics, Inc. Common Stock

RLMDNASDAQ • USD
ThemeBiotech - Drug Development›Rare Disease Therapeutics
3.28 USD
↘ 0.20 (5.75%)AT CLOSE (03:59 PM EDT)
3.27
↘ 0.01 (0.46%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
3.27
↘ 0.01 (0.46%)
🔴Market: CLOSED

Shares of Relmada Therapeutics, Inc. Common Stock (RLMD) are trading at $3.28. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, RLMD appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Oct 6, 2026.

Open?$3.50
High?$3.50
Low?$3.27
Prev. Close?$3.48
Volume?1.7M
Avg. Volume?1.2M
VWAP?$3.33
Rel. Volume?1.47x
Bid / Ask
Bid?$2.82 × 100
Ask?$3.92 × 100
Spread?$1.10
Midpoint?$3.37
Valuation & Ratios
Market Cap?371.2M
Shares Out?106.7M
Float?86.9M
Float %?81.5%
P/E Ratio?N/A
P/B Ratio?1.80
EPS?-$0.58
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Themes
Biotech - Drug Development›Rare Disease TherapeuticsBiotech - Drug Development›Neuroscience & CNSHealthcare - Oncology›Targeted Therapy & Precision Oncology
Employees
17
Market Cap
371.2M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.relmada.com
Listed
2014-03-03
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR
CORAL GABLES, FL 33134
Phone: 646 876 3459
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
20
Piotroski F-Score?0/9Weak
Altman Z-Score?13.33Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?16.64%High
Short Interest?14.5M
Days to Cover?9.3
Free Float86.9M
Avg Daily Volume1.6M
Settlement Date2026-09-15
Financial Health
Current Ratio?29.52Strong
Quick Ratio?29.52Strong
Cash Ratio?1.53Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
80
1.80CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-5.5CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
6
-30.0%WEAK▾
ROA?
S&P
3
-28.3%WEAK▾
Cash Flow & Enterprise
FCF?$-45992000
Enterprise Value?$359.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist